Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

医学 脂肪性肝炎 肝活检 脂肪肝 内科学 胃肠病学 纤维化 活检 石蕊 病理 疾病 物理化学 化学
作者
Yasaman Vali,Jenny Lee,Jérôme Boursier,Salvatore Petta,Kristy Wonders,Dina Tiniakos,Pierre Bédossa,Andreas Geier,Sven Francque,Mike Allison,George Papatheodoridis,Helena Cortêz-Pinto,Raluca Pais,Jean‐François Dufour,Diana Julie Leeming,Stephen A. Harrison,Yu Chen,Jeremy Cobbold,Michael Pavlides,Adriaan G. Holleboom,Hannele Yki‐Järvinen,Javier Crespo,M.A. Karsdal,Rachel Ostroff,Mohammad Hadi Zafarmand,Richard Torstenson,Kevin L. Duffin,Carla Yunis,Clifford A. Brass,Mattias Ekstedt,Guruprasad P. Aithal,Jörn M. Schattenberg,Elisabetta Bugianesi,Manuel Romero‐Gómez,Vlad Ratziu,Quentin M. Anstee,Patrick M. Bossuyt
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (8): 714-725 被引量:84
标识
DOI:10.1016/s2468-1253(23)00017-1
摘要

Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis-liver biopsy-is invasive and resource intensive.Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in a single cohort.As part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, we aimed to evaluate the diagnostic accuracy of 17 biomarkers and multimarker scores in detecting NASH and clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and identify their optimal cutoffs as screening tests in clinical trial recruitment.Methods This was a comparative diagnostic accuracy study in people with biopsy-confirmed NAFLD from 13 countries across Europe, recruited between Jan 6, 2010, and Dec 29, 2017, from the LITMUS metacohort of the prospective European NAFLD Registry.Adults (aged ≥18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence of other chronic liver diseases were excluded.The diagnostic accuracy of the biomarkers was expressed as the area under the receiver operating characteristic curve (AUC) with liver histology as the reference standard and compared with the Fibrosis-4 index for liver fibrosis (FIB-4) in the same subgroup.Target conditions were the presence of NASH with clinically significant fibrosis (ie, at-risk NASH; NAFLD Activity Score ≥4 and F≥2) or the presence of advanced fibrosis (F≥3), analysed in all participants with complete data.We identified thres holds for each biomarker for reducing the number of biopsybased screen failures when recruiting people with both NASH and clinically significant fibrosis for future trials.Findings Of 1430 participants with NAFLD in the LITMUS metacohort with serum samples, 966 (403 women and 563 men) were included after all exclusion criteria had been applied.335 (35%) of 966 participants had biopsy-confirmed NASH and clinically significant fibrosis and 271 (28%) had advanced fibrosis.For people with NASH and clinically significant fibrosis, no single biomarker or multimarker score significantly reached the predefined AUC 0•80 acceptability threshold (AUCs ranging from 0•61 [95% CI 0•54-0•67] for FibroScan controlled attenuation parameter to 0•81 [0•75-0•86] for SomaSignal), with accuracy mostly similar to FIB-4.Regarding detection of advanced fibrosis, SomaSignal (AUC 0•90 [95% CI 0•86-0•94]), ADAPT (0•85 [0•81-0•89]), and FibroScan liver stiffness measurement (0•83 [0•80-0•86]) reached acceptable accuracy.With 11 of 17 markers, histological screen failure rates could be reduced to 33% in trials if only people who were marker positive had a biopsy for evaluating eligibility.The best screening performance for NASH and clinically significant fibrosis was observed for SomaSignal (number needed to test [NNT] to find one true positive was four [95% CI 4-5]), then ADAPT (six [5-7]), MACK-3 (seven [6-8]), and PRO-C3 (nine [7-11]).Interpretation None of the single markers or multimarker scores achieved the predefined acceptable AUC for replacing biopsy in detecting people with both NASH and clinically significant fibrosis.However, several biomarkers could be applied in a prescreening strategy in clinical trial recruitment.The performance of promising markers will be further evaluated in the ongoing prospective LITMUS study cohort.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
她与星辰皆失完成签到 ,获得积分10
2秒前
小本本发布了新的文献求助10
3秒前
5秒前
健忘曼冬发布了新的文献求助10
6秒前
猪猪发布了新的文献求助30
7秒前
大模型应助无限映波采纳,获得10
7秒前
7秒前
8秒前
9秒前
桐桐应助grace采纳,获得10
10秒前
10秒前
诺贝尔候选人完成签到 ,获得积分10
11秒前
556应助仲达采纳,获得10
11秒前
boshi发布了新的文献求助10
11秒前
小菜发布了新的文献求助10
12秒前
北风完成签到,获得积分10
15秒前
Serena510完成签到 ,获得积分10
15秒前
慕青应助欣慰的乌冬面采纳,获得10
16秒前
ding应助方仔采纳,获得10
17秒前
hhhh应助bliss采纳,获得20
17秒前
18秒前
大个应助苗条的辣辣采纳,获得10
18秒前
猪猪完成签到,获得积分10
19秒前
19秒前
研友_ngkEgn完成签到,获得积分10
19秒前
赘婿应助小菜采纳,获得10
19秒前
完美世界应助shinn采纳,获得30
21秒前
22秒前
LYSM应助一言矣采纳,获得10
22秒前
CC完成签到 ,获得积分10
22秒前
可靠的嫣然完成签到,获得积分10
22秒前
zys发布了新的文献求助30
22秒前
grace发布了新的文献求助10
23秒前
kkk发布了新的文献求助10
24秒前
英姑应助老迟到的沛萍采纳,获得10
24秒前
aaaaaa完成签到,获得积分10
24秒前
Janson完成签到,获得积分10
25秒前
ding应助英勇的人生采纳,获得10
26秒前
Orange应助哈哈采纳,获得10
27秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975339
求助须知:如何正确求助?哪些是违规求助? 3519670
关于积分的说明 11199199
捐赠科研通 3256002
什么是DOI,文献DOI怎么找? 1798043
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305